Rebecca Seufert

No ORCID on file · 1 paper in corpus

article 2014

A first-in-human study of PDC31 (prostaglandin F2 receptor inhibitor) in primary dysmenorrhea

·doi:10.1093/humrep/deu205

STUDY QUESTION: What is the safe and pharmacodynamically active dose range for PDC31 (prostaglandin F2α receptor inhibitor) in patients with primary dysmenorrhea (PD)? SUMMARY ANSWER: The 1 mg/kg/h dose of PDC31 appears to be safe and poten…